Researchers examine the mechanisms responsible for the increased risk of neurocognitive impairment in HIV patients and explore potential treatments.
Median lag between FDA authorization and Medicare coverage hits 6 years: study
Dive Brief: Fewer than 30% of novel medical devices receive nominal or better coverage from Medicare in the three years after regulatory authorization, according to
August 11, 2023